Swiss National Bank grew its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 2.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 63,800 shares of the company’s stock after buying an additional 1,600 shares during the period. Swiss National Bank owned 0.17% of Omnicell worth $3,094,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in OMCL. Marco Investment Management LLC acquired a new stake in shares of Omnicell in the third quarter valued at approximately $231,000. Stevens Capital Management LP purchased a new position in shares of Omnicell during the third quarter valued at approximately $305,000. Sei Investments Co. lifted its stake in shares of Omnicell by 76.7% during the third quarter. Sei Investments Co. now owns 8,219 shares of the company’s stock valued at $420,000 after buying an additional 3,567 shares during the period. Shelton Capital Management lifted its stake in shares of Omnicell by 17.6% during the fourth quarter. Shelton Capital Management now owns 9,800 shares of the company’s stock valued at $475,000 after buying an additional 1,464 shares during the period. Finally, Janney Capital Management LLC lifted its stake in shares of Omnicell by 45.3% during the third quarter. Janney Capital Management LLC now owns 9,484 shares of the company’s stock valued at $484,000 after buying an additional 2,957 shares during the period.
Shares of Omnicell, Inc. (NASDAQ OMCL) traded down $0.45 during trading hours on Wednesday, reaching $44.10. 149,034 shares of the company traded hands, compared to its average volume of 381,784. Omnicell, Inc. has a 12-month low of $37.90 and a 12-month high of $55.40. The company has a market cap of $1,710.00, a P/E ratio of 315.00, a PEG ratio of 3.76 and a beta of 0.75. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.28 and a current ratio of 1.73.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.02. The company had revenue of $198.26 million for the quarter, compared to the consensus estimate of $205.50 million. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. Omnicell’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.37 EPS. sell-side analysts anticipate that Omnicell, Inc. will post 0.77 EPS for the current fiscal year.
In other Omnicell news, Chairman Randall A. Lipps sold 8,186 shares of Omnicell stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total value of $361,903.06. Following the completion of the sale, the chairman now directly owns 224,206 shares in the company, valued at $9,912,147.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Peter J. Kuipers sold 1,926 shares of Omnicell stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the sale, the chief financial officer now owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The disclosure for this sale can be found here. Insiders own 3.77% of the company’s stock.
A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Oppenheimer reissued a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research report on Tuesday, December 5th. Craig Hallum lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $63.00 price target on shares of Omnicell in a report on Thursday, February 1st. Finally, Piper Jaffray Companies raised their price objective on shares of Omnicell from $38.00 to $44.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $56.14.
TRADEMARK VIOLATION WARNING: This piece was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/03/14/swiss-national-bank-has-3-09-million-position-in-omnicell-inc-omcl.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.